- Home
- UOKA vs QLGN Comparison
UOKA vs QLGN Comparison
Compare UOKA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UOKA
- QLGN
- Stock Information
- Founded
- UOKA 2002
- QLGN 1996
- Country
- UOKA United Kingdom
- QLGN United States
- Employees
- UOKA N/A
- QLGN N/A
- Industry
- UOKA
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- UOKA
- QLGN Health Care
- Exchange
- UOKA NYSE
- QLGN Nasdaq
- Market Cap
- UOKA 2.7M
- QLGN 2.8M
- IPO Year
- UOKA N/A
- QLGN N/A
- Fundamental
- Price
- UOKA $2.40
- QLGN $3.54
- Analyst Decision
- UOKA
- QLGN
- Analyst Count
- UOKA 0
- QLGN 0
- Target Price
- UOKA N/A
- QLGN N/A
- AVG Volume (30 Days)
- UOKA 128.0K
- QLGN 9.1K
- Earning Date
- UOKA 08-16-2025
- QLGN 08-13-2025
- Dividend Yield
- UOKA N/A
- QLGN N/A
- EPS Growth
- UOKA N/A
- QLGN N/A
- EPS
- UOKA N/A
- QLGN N/A
- Revenue
- UOKA $48,375.00
- QLGN N/A
- Revenue This Year
- UOKA N/A
- QLGN N/A
- Revenue Next Year
- UOKA N/A
- QLGN N/A
- P/E Ratio
- UOKA N/A
- QLGN N/A
- Revenue Growth
- UOKA N/A
- QLGN N/A
- 52 Week Low
- UOKA $1.98
- QLGN $2.85
- 52 Week High
- UOKA $42.50
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- UOKA N/A
- QLGN 44.87
- Support Level
- UOKA N/A
- QLGN $3.37
- Resistance Level
- UOKA N/A
- QLGN $3.85
- Average True Range (ATR)
- UOKA 0.00
- QLGN 0.23
- MACD
- UOKA 0.00
- QLGN -0.03
- Stochastic Oscillator
- UOKA 0.00
- QLGN 34.29
About UOKA MDJM LTD
MDJM Ltd is engaged in providing real estate agency services to its real estate developer clients, and provides, on an as-needed basis, real estate consulting services and independent training services. The company generates all of its revenue from Hotel income. The company derives a majority of its revenue from the United Kingdom.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.